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Abstract
Background: Type 1 diabetes (T1D) is a common autoimmune disease resulting from T-cell
mediated destruction of pancreatic beta cells. Decay accelerating factor (DAF, CD55), a
glycosylphosphatidylinositol-anchored membrane protein, is a candidate for autoimmune disease
susceptibility based on its role in restricting complement activation and evidence that DAF
expression modulates the phenotype of mice models for autoimmune disease. In this study, we
adopt a linkage disequilibrium (LD) mapping approach to test for an association between the DAF
gene and T1D.
Results:  Initially, we used HapMap II genotype data to examine LD across the DAF region.
Additional resequencing was required, identifying 16 novel polymorphisms. Combining both
datasets, a LD mapping approach was adopted to test for association with T1D. Seven tag SNPs
were selected and genotyped in case-control (3,523 cases and 3,817 controls) and family (725
families) collections.
Conclusion: We obtained no evidence of association between T1D and the DAF region in two
independent collections. In addition, we assessed the impact of using only HapMap II genotypes for
the selection of tag SNPs and, based on this study, found that HapMap II genotypes may require
additional SNP discovery for comprehensive LD mapping of some genes in common disease.
Background
T1D is characterised as a common autoimmune disease,
mainly resulting from a T-cell mediated destruction of
pancreatic beta cells that leaves patients completely
dependent on exogenous insulin to regulate their blood
glucose level. T1D is strongly clustered in families with an
Published: 20 April 2006
BMC Genetics 2006, 7:22 doi:10.1186/1471-2156-7-22
Received: 22 February 2006
Accepted: 20 April 2006
This article is available from: http://www.biomedcentral.com/1471-2156/7/22
© 2006 Taniguchi et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Genetics 2006, 7:22 http://www.biomedcentral.com/1471-2156/7/22
Page 2 of 9
(page number not for citation purposes)
LD map for human DAF region on Chromosome 1q32 Figure 1
LD map for human DAF region on Chromosome 1q32. All markers with the MAF of less than 0.05 or with insufficient 
genotyping data were excluded in the LD measurement. a. LD map with 21 markers genotyped in 60 individuals obtained from 
HapMap II. b. LD map with 22 markers identified by resequencing with 32 CEPH's individuals. figure c. LD map with 38 mark-
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overall genetic risk ratio, an estimate of the familial clus-
tering of the disease, of approximately 15[1]. However, of
the hundreds of association studies reported to date, only
four loci have been identified and successfully replicated:
the HLA class II genes on chromosome 6p21[2]; the insu-
lin gene (INS) on chromosome 11p15[3,4]; CTLA4 on
chromosome 2q33[5,6]; and PTPN22  on chromosome
1p13[7,8]. CD25 on chromosome 10p15 has been impli-
cated, but this finding awaits independent replication[9].
Given that these genes alone cannot explain the familial
clustering of T1D, many other genes remain to be identi-
fied.
Recently, there have been several reports focusing on the
relationship between autoimmune disease and the com-
plement system, which is composed of more than 30 sol-
uble and membrane-bound proteins[10,11] and plays an
important role in innate host defence. As inappropriate
regulation of the complement system can lead to signifi-
cant damage of host tissues[12], a number of membrane-
bound complement regulatory proteins are active, such as
DAF, a glycosylphosphatidylinositol-anchored mem-
brane protein that restricts complement activation by
inhibiting the formation of C3 convertases in both the
classical and alternative pathways[13,14].
Dysfunction of human DAF on erythrocytes contributes
to the paroxysmal nocturnal hemoglobinuria (PNH) by
increasing their sensitivity to complement lysis[13,15,16].
In addition, a proportion of DAF-deficient (Cromer
INAB) patients develop inflammatory bowel disease.
However, little is known about DAFs role in autoimmune
disease in vivo[17].
Recently, it has been reported that DAF modulates T cell
immunity by controlling T cell- and antigen-presenting
cell- induced alternative pathway of C3 activation during
cognate interactions [18-20]. According to gene targeting
studies, mice deficient in the DAF1 gene, the murine
homologue of human DAF, showed more susceptibility to
complement mediated inflammatory injury, especially
DAF1 deficient female mice in a MRL/lpr background, a
model for human systemic lupus erythematosus, which
showed aggravated lymphadenopathy and splenomegaly,
higher serum anti-chromatin autoantibody levels, and
dermatitis[21].
Given this prior evidence, DAF may function as a negative
regulator of autoimmune response by modulating T cell
activity and directly protecting host tissues in vivo and that
recombinant DAF may be an ideal therapeutic agent for
autoimmunity[22]. On the other hand, DAF does not lie
under any of the reported T1D linkage peaks[23,24] nor
have there been any reports of genetic association studies
between DAF and autoimmune disease, although recently
differential expression of DAF was observed when com-
paring T cells from nonobese diabetic (NOD) mice and
diabetes-resistant NOD mice having a congenic interval
containing the DAF gene thereby making it a candidate
gene for the Idd5.4 region (William Ridgway and Linda
Wicker, unpublished observations).
In this study, to elucidate the susceptibility of DAF with
T1D, we performed an association study using a LD map-
ping approach, together with the direct analysis of three




Initially, we used phase II genotyping data from the Hap-
Map project[25,26], a catalogue of common human
genetic variants, providing their allele frequencies and
intermarker LD patterns among people, within and
among populations from African, Asian, and European
ancestry. In the DAF region, about 40 kb on chromosome
1q32, 21 common SNPs (minor allele frequency (MAF) ≥
0.05), have been genotyped in 60 U.S.A. residents with
northern and western European ancestry, collected in
1980 by the Centre d'Etude du Polymorphisme Humain
(CEPH, CEU). We note that all of these SNPs were located
in non-coding regions and that the average inter-SNP dis-
tance was 2 kb. A LD map of the region, using pairwise D',
shows little evidence of recombination within the region
(Figure 1a).
DAF resequencing
As we were concerned about adopting a LD mapping
approach given the HapMap SNP density[27], we rese-
quenced DAF in 32 CEPH individuals, selected from the
60 CEPH individuals used by the HapMap project, to
increase the SNP density across the region.
Analysis of the resequencing data identified 32 polymor-
phisms, 26 of which were SNPs and six were deletion/
insertion polymorphisms (DIPs), of which 12 SNPs and
four DIPs were novel when compared to dbSNP build 125
(Table 1). Twenty-two polymorphisms were common
(MAF ≥ 0.05), five of which were also found in the Hap-
Map II data. The relatively small number of common pol-
ymorphisms found in both datasets is not unexpected, as
HapMap II SNPs were selected to provide an even cover-
age in terms of distance across the genome, whereas the
resequencing is focused on regions of interest and extracts
all common polymorphisms present in these individuals.
A LD map of the region, based on these 22 polymor-
phisms (Figure 1b), revealed additional evidence of
recombination within the region over and above that
apparent in HapMap II data alone (Figure 1a). There wasBMC Genetics 2006, 7:22 http://www.biomedcentral.com/1471-2156/7/22
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Table 1: Polymorphisms identified in human DAF. Map positions on human chromosome 1 were from NCBI build 35. Selected tag 
SNPs are in boldface. Alleles are coded Major > Minor. MAF calculated from the 32 individuals used for tag SNP selection, except for 
nsSNPs, in which case the MAF is calculated from genotyped controls. DIL = identified by in-house resequencing, HapMap = identified 
in HapMap II dataset, DIL&HapMap II = Identified in both in-house resequencing and HapMap II dataset.




ss49853051(G > C) 203881344 promoter 0.03 - DIL
ss49853052(C > T) 203881734 promoter 0.03 - DIL
rs6685886(C > A) 203882613 promoter 0.46 85.07 DIL
rs2564978(C > T) 203882811 promoter 0.33 tag SNP DIL & HapMap
rs3841376 (TAGTTACTTCCCCTCCTTCCC > -) 203882879 promoter 0.33 100.00 DIL
ss49853053(A > G) 203883074 promoter 0.26 tag SNP DIL
ss49853054(T > C) 203883723 intron 1 0.02 - DIL
rs7533852(G > T) 203883822 intron 1 0.44 89.15 DIL
ss49853055(TA > -) 203884424 intron 2 0.03 - DIL
rs4844590(C > T) 203884524 intron 2 0.23 tag SNP DIL
rs2782828(G > T) 203885394 intron 2 0.24 94.47 HapMap
ss49853056(A > G) 203886206 intron 2 0.03 - DIL
ss49853057(C > G) 203887670 intron 4 0.13 tag SNP DIL
ss49853058(G > A) 203888427 intron 4 0.03 - DIL
rs4844591(T > C) 203888688 intron 5 0.33 90.27 DIL & HapMap
rs4844592(A > T) 203889606 intron 5 0.33 90.27 HapMap
rs6703002(G > T) 203890767 intron 5 0.32 88.10 HapMap
rs6700168(C > A) 203890929 intron 5 0.38 82.68 HapMap
rs925130(A > G) 203891827 intron 5 0.33 100.00 HapMap
rs925131(G > A) 203892116 intron 5 0.33 90.27 HapMap
ss49853059(C > T) 203892582 intron 5 0.02 - DIL
rs2184476(A > G) 203893064 intron 6 0.45 tag SNP DIL
rs1507757(A > C) 203893143 intron 6 0.35 tag SNP DIL
rs6662070(G > A) 203894104 intron 6 0.31 100.00 HapMap
rs1507758(C > G) 203895876 intron 6 0.33 90.27 HapMap
rs1507759(G > A) 203896023 intron 6 0.32 100.00 HapMap
rs12075906(A > G) 203896494 intron 6 0.33 100.00 HapMap
rs1354942(A > G) 203896887 intron 6 0.33 90.27 HapMap
rs7555030(G > A) 203897125 intron 6 0.33 100.00 HapMap
rs7544288(G > A) 203897417 intron 6 0.41 97.09 HapMap
rs1507760(T > C) 203897760 intron 6 0.33 100.00 HapMap
rs1507761(C > T) 203898194 intron 6 0.33 100.00 HapMap
ss49853060(C > T) 203898910 intron 7 0.04 - DIL
rs10746462(G > A) 203898943 intron 7 0.33 90.27 DIL
rs10746463(A > G) 203898991 intron 7 0.33 90.27 DIL & HapMap
ss49853061(G > A) 203899255 intron 8 0.02 - DIL
rs2135923(G > A) 203914988 intron 10 0.33 90.27 HapMap
ss49853066(- > TT) 203921271 intron 10 0.39 97.09 DIL
ss49853062(A > G) 203922987 3' 0.02 - DIL
rs11120766(A > G) 203923074 3' 0.45 84.94 DIL
rs1507765(A > C) 203923641 3' 0.45 84.94 DIL & HapMap
rs11307618(A > -) 203923723 3' 0.41 97.09 DIL
ss49853063(A > G) 203923730 3' 0.41 97.09 DIL
ss49853064(C > -) 203923933 3' 0.39 91.71 DIL
rs12066318(T > C) 203924026 3' 0.33 tag SNP DIL
ss49853065(- > ATG) 203924418 3' 0.45 84.94 DIL
rs11120769(G > T) 203925240 3' 0.45 83.28 DIL
rs11117564(C > A) 203925366 3' 0.45 90.45 DIL & HapMap
nsSNPs
rs28371588(>) 203884176 Exon 2 0.05 -BMC Genetics 2006, 7:22 http://www.biomedcentral.com/1471-2156/7/22
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a breakdown in LD towards the 5' end of DAF that was not
evident in HapMap II data.
Tag SNP analysis of DAF
To test for an association between T1D and the DAF
region, we adopted a LD mapping approach, which
exploits the non-random relationships between SNPs
(known as LD) in a region of interest to reduce the
amount of genotyping required. As the causal SNP is
unknown, we assume that predicting the causal SNP is
likely to be no more difficult than predicting any other
SNP. The predictive performance of the tag SNPs was
assessed using a R2 measure, which measures the ability to
predict each known SNP by multiple regression on the set
of tag SNPs. The tag SNPs were analysed using a multilo-
cus test, as described by Chapman et al[28], which tests for
an association between the tag SNPs and T1D due to LD
with one or more causal variants[28,29].
We first combined our resequencing data with the Hap-
Map data, providing a panel of 38 common polymor-
phisms genotyped in 32 individuals (Table 1), and
generated a combined LD map of the region (Figure 1c).
Subsequently, seven tag SNPs were selected[9] from the
38 common polymorphisms, required to capture the var-
iation within the DAF  region with a minimum R2 of
0.80[28] (Table 1). The tag SNPs were genotyped in 3,523
cases and 3,817 controls, and in 725 Caucasian multiplex
T1D families (Table 2). The case-control and family mul-
tilocus P-values were 0.12 (3,523 case and 3,817 control
genotypes; F7,7321 = 1.63) and 0.69 (parent-child trio gen-
otypes = 1,390; χ7
2 = 4.72), respectively, providing no evi-
dence for the association between T1D and the DAF
region. In the case-control collection, the multilocus test
was stratified by broad geographical within the UK in
order to minimize any confounding due to variation in
allele frequencies across Great Britain[9,30].
DAF-WESa/b(T > G) 203884266 Exon 2 0.00
55
-
rs12135160(>) 203899090 Exon 8 - -
Table 1: Polymorphisms identified in human DAF. Map positions on human chromosome 1 were from NCBI build 35. Selected tag 
SNPs are in boldface. Alleles are coded Major > Minor. MAF calculated from the 32 individuals used for tag SNP selection, except for 
nsSNPs, in which case the MAF is calculated from genotyped controls. DIL = identified by in-house resequencing, HapMap = identified 
in HapMap II dataset, DIL&HapMap II = Identified in both in-house resequencing and HapMap II dataset. (Continued)
Table 2: Genotyping data of tag SNPs. The number of individuals with each genotype in case-control data and the number of alleles in 
family data are indicated. T, Transmitted. UT, Untransmitted. MAF, minor allele frequency calculated from either control samples or 
parents.
Case-Control Family





Case 0.31 1648 1468 318 UK 0.32 738 483 458
Control 0.31 1791 1622 354 USA 0.27 526 272 289
ss4985305
3(A > G)
Case 0.25 1895 1305 219 UK 0.24 736 345 350
Control 0.24 2147 1338 231 USA 0.29 536 317 304
rs4844590
(C > T)
Case 0.23 1987 1194 193 UK 0.21 711 287 309
Control 0.22 2288 1251 195 USA 0.26 517 272 270
ss4985305
7(C > G)
Case 0.07 2914 465 22 UK 0.08 709 113 101
Control 0.08 3071 580 17 USA 0.06 527 62 62
rs2184476
(A > G)
Case 0.31 1607 1447 314 UK 0.33 723 475 442
Control 0.31 1757 1578 345 USA 0.27 492 249 268
rs1507757
(A > C)
Case 0.31 1660 1469 319 UK 0.33 736 484 479
Control 0.31 1756 1586 349 USA 0.27 476 246 248
rs1206631
8(A > G)
Case 0.44 658 1679 1104 UK 0.43 751 866 859
Control 0.45 738 1868 1135 USA 0.44 538 597 605BMC Genetics 2006, 7:22 http://www.biomedcentral.com/1471-2156/7/22
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Analysis of DAF non-synonymous SNPs
Recently, it has been proposed that complex diseases such
as T1D may result from the effects of a large number of
rare variants, with substantial allelic heterogeneity at
causal loci[31,32]. In DAF, several rare non-synonymous
SNPs (nsSNPs) were reported in the exons encoding the
short consensus repeat (SCR) domains of the DAF pro-
tein, which have subsequently been shown to be related
with antigen of the Cromer blood group sys-
tem[13,14,33,34]. On the basis of the rare variant hypoth-
esis, we genotyped three rare nsSNPs in3,490 cases and
3,814 controls (Table 3), under the hypothesis that a rare
functional variant in DAF might have a strong effect in
T1D. The following three nsSNPs were assessed: DAF-
WESa/b(G > T) located in exon 2 with a MAF of 0.0055–
0.0060 in a Finnish population[35,36]; rs28371588(C >
A), also located in exon 2[34]; and, rs12135160(G > A),
identified by SsahaSNP detection tool (NIH and Sanger
Institute, UK) in exon 8 and not previously genotyped. All
result in amino-acid substitutions, but their phenotypic
influences have not been characterized. In the present
study, the MAF of rs12135160(G > A) was 0.00042 in
3,768 controls, and consequently, we have no statistical
power to detect an association. Both rs28371588(C > A)
and DAF-WESa/b(G > T) were monomorphic in the case-
control collection.
Discussion
In this study, we did not find any evidence for an associa-
tion between T1D and the DAF region in large case-con-
trol and family collections using a LD mapping approach.
We combined the HapMap II genotyping data and rese-
quencing data, for the selection of tag SNPs. Had we cho-
sen the tag SNPs using only the HapMap II genotyping
data, only two tag SNPs (rs2564978 and rs1507765) were
required to capture the detected variation within the ~40
kb  DAF  region with a minumum R2 of 0.8. However,
when the predictive performance of the two tag SNPs were
applied to the combined sequence dataset, they no longer
captured the variation within the region to the required
level since seven of the thirty-six common polymor-
phisms had an R2 below 0.8. The inability of the tag SNPs
selected from HapMap II data to tag the combined dataset
(minimum R2 = 0.35) suggests that for the analysis of
localized regions containing candidate genes, as opposed
to whole-genome association studies, HapMap II data
alone may not provide sufficient information to facilitate
a comprehensive LD-mapping approach. In the tag SNP
approach, as the causal variant is unknown, we assume
that the problem of predicting the causal polymorphism
is likely to be no more difficult than that of predicting any
other polymorphism[28]. Consequently, the power of the
tag SNP approach to detect a causal polymorphism is
based upon the minimum R2[28], assuming that the
majority of common polymorphisms in a region are
known. In this instance, incomplete knowledge of the
common polymorphisms in a region inflated the mini-
mum R2, providing false confidence in the ability of the
tag SNPs to capture the variation within a region, and in
the power to detect a causal variant. Our results indicate
that for some genes/regions HapMap II data may need to
be supplemented by additional resequencing data to
allow comprehensive association mapping of common
variants.
Conclusion
We conclude that variation in DAF itself is unlikely to
have a major effect in T1D in these populations. Analysis
of an extended region, surrounding the DAF region ana-
lysed in this study, showed a cluster of several other genes
involved in the complement system, including C4b bind-
ing protein (C4bp) and membrane cofactor protein
(MCP), both known regulators of complement activation
(RCA) genes[11,37,38]. C4bp and MCP restrict comple-
ment activation by inhibiting the formation of C3 conver-
tases in the classical pathways like DAF, suggesting that
they modulate each other in direct and indirect ways. To
clarify the relation of autoimmune disease and comple-
ment system, including DAF, further genetic association
studies and functional studies on RCA genes are needed.
The set of tag SNPs and the LD map for the DAF region
will be useful for such further studies.
Methods
Subjects
The resequencing panel consisted of 32 CEPH individu-
als; Utah residents with ancestry from Northern and West-
Table 3: Genotyping data of non-synonymous SNPs. The numbers of individuals with each genotype in case-control data are indicated. 
MAF, minor allele frequency calculated from control samples.
SNP Population MAF 1/1 1/2 2/2
rs28371588(C > A) Case 0 3420 0 0
Control 0 3748 0 0
DAF-WESa/b(T > G) Case 0 3438 0 0
Control 0 3738 0 0
rs12135160(G > A) Case 0.0004 3437 3 0
Control 0.0004 3765 3 0BMC Genetics 2006, 7:22 http://www.biomedcentral.com/1471-2156/7/22
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ern Europe collected in 1980 by the Centre d'Etude du
Polymorphisme Humain (CEPH).
The 3,523 cases were recruited as part of the Juvenile Dia-
betes Research Foundation/Wellcome Trust Diabetes and
Inflammation Laboratory's United Kingdom Genetic
Resource Investigating Diabetes (U.K. GRID) study, which
is a joint project between the University of Cambridge
Department of Paediatrics and the Department of Medical
Genetics at the Cambridge Institute for Medical Research.
Most cases were < 16 years of age at the time off collection,
all resided in Great Britain, and all were of European
descent (self-reported). The 3,817 control samples were
obtained from the 1958 British Birth Cohort (1958 BBC),
an ongoing follow-up of all person born in Great Britain
during one week in 1958 (National Child Development
Study)[39]. All cases and control were of white ethnicity.
All families were Caucasian and of European descent,
with two parents and at least one affected child. The fam-
ily collection consisted of 457 multiplex families from the
U.K. British Diabetic Association Warren 1 repository[40]
and 268 multiplex families from U.S.A. Human Biological
Data Interchange[41].
The Cambridge Local Research Ethics Committee gave full
ethical approval, and informed consent was obtained for
the collection and use of these DNA samples from all sub-
jects.
DAF resequencing
We first annotated the DAF gene locally[42,43] and dis-
played the annotation through gbrowse[44] within
T1DBase[45], using these annotations we resequenced all
11 exons, exon/intron boundaries and up to 3 kb of 3' and
5' flanking sequence of the DAF gene in 32 CEPH individ-
uals, to increase the SNP density across the region. The
sequencing reactions were carried out on nested PCR
products using Applied Biosystems (ABI) BigDye termina-
tor v3.1 chemistry and the sequences resolved on an
ABI3700 DNA Analyser. Polymorphisms were identified
using the Staden Package [46] and double-scored by a sec-
ond operator.
Statistical analysis
The multilocus test has been described in detail else-
where[9,28,29,47], briefly, for the case-control data, the
multilocus test is essentially Hotellings T2[48,49], in
which we score each diallelic locus as 0, 1 or 2 and com-
pare the mean score vectors between cases and control. In
the case of the family data, the multilocus test takes the
form of a multilocus TDT[28], in which, for each parent,
we calculate a vector whose elements describe transmis-
sions of each of the tag SNPs. If the parent is homozygous
at a locus, the corresponding element is scored as zero,
otherwise it scored as either +1 or -1 depending on which
allele was transmitted. The multilocus test tests the mean
of this vector against zero; it is asymptotically distributed
as a χ2 with degrees of freedom (df) equal to the number
of tag SNPs[28,47].
The program for the selection of tag SNPs[28] and associ-
ation analysis used here are implemented in the Stata sta-
tistical system and may be downloaded from our
website[50].
Genotyping
Genotyping was performed using Taqman MGB (Applied
Biosytems Inc, Foster City, CA)[51]. All genotyping data
were double-scored to minimize error. All genotyping
data were in Hardy-Weinberg equilibrium (P  > 0.05).
Genotyping failure rates for all assays in both the family
and case-control collection were ≤ 6%.
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